Sangamo Therapeutics
uses zinc-finger transcription factors rather than dCas9 as its DNA-binding scaffold, partnering with Genentech to develop an epigenetic Alzheimer's therapy and holding patent filings on zinc-finger repressors targeting alpha-synuclein.
- Country
- United States
zinc-finger
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Epigenome editing | genome-engineering | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.